Tag: praluent market forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Praluent Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

Historical growth was driven by an escalating incidence of high cholesterol, the shortcomings of treatments solely based on statins, enhanced screening for cardiovascular risk, a wider availability of biologic medications for heart conditions, and the expansion of specialized cardiology services.

The anticipated growth during the forecast period is driven by an increased emphasis on aggressive lipid-lowering strategies, broader implementation in secondary prevention, the expansion of value-based cardiovascular care, rising payer support for pcsk9 inhibitors, and a heightened awareness regarding cardiovascular risk reduction.

Prominent trends in the forecast period include the increasing utilization of pcsk9 inhibitors in lipid management, greater adoption among high-risk cardiovascular patients, the growing integration with statin combination therapy, the proliferation of preventive cardiology programs, and a stronger focus on long-term LDL control.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=72717625&type=smp&name=Praluent%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Praluent Market Growth Momentum: What Factors Are Shaping Demand?

The increasing trend of obesity is anticipated to boost the expansion of the Praluent market moving ahead. Obesity denotes a health condition marked by an excessive buildup of body fat, which presents health risks, commonly identified by a Body Mass Index (BMI) of 30 or above. The growing incidence of obesity primarily stems from changes in global dietary patterns and food systems, exemplified by greater intake of ultra-processed items, inactive lifestyles, and economic factors that make less healthy food options more accessible. Praluent assists in managing obesity by lowering LDL cholesterol levels in individuals suffering from obesity-related dyslipidemia. As a PCSK9 inhibitor, it improves the liver’s capacity to clear LDL cholesterol from the bloodstream, thereby enhancing cardiovascular well-being and mitigating complications linked to obesity. For instance, in May 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department responsible for maintaining public health policies, 64.0% of adults (18+) in England were estimated to be overweight or living with obesity in the period 2022–2023, while 26.2% were estimated to be living with obesity (BMI = 30 kg/m²). Consequently, the surge in obesity will propel the Praluent market’s growth. The expanding uptake of personalized medicine is anticipated to fuel the growth of the Praluent market moving forward. Personalized medicine refers to a medical approach where healthcare professionals customize treatments based on individual biological characteristics to enhance patient outcomes. The adoption of personalized medicine is increasing because clinicians increasingly favor therapies that align with specific genetic and biomarker profiles, leading to greater treatment accuracy. Praluent supports the expanding use of personalized medicine as its targeted PCSK9-inhibiting mechanism allows clinicians to customize LDL-cholesterol reduction according to individual cardiovascular-risk profiles. For instance, in February 2025, according to BioSpace, Inc., a U.S.-based life science news site, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Consequently, the rising adoption of personalized medicine is expected to propel the Praluent market’s growth.

Praluent Market Segmentation And Category Overview

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Praluent Market Trends Redefining Industry Growth

Major companies in the praluent market are prioritizing the development of innovative solutions, such as therapies aimed at reducing low-density lipoprotein cholesterol (LDL-C), to fulfill the increasing demand for advanced treatments for cardiovascular risk reduction. These LDL-C–lowering therapies are specialized medical interventions engineered to significantly decrease “bad cholesterol” levels, offering more precise, targeted, and enduring lipid control compared to traditional statins or lifestyle changes alone. For example, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, secured extended approval from the U.S. Food and Drug Administration (FDA) for its Praluent (alirocumab) injection, an advanced biologic therapy for lowering LDL-C. This updated approval permits its use as an adjunctive treatment to diet and current lipid-lowering therapies for pediatric patients aged 8 years and older diagnosed with heterozygous familial hypercholesterolemia (HeFH). Praluent operates as a PCSK9 inhibitor monoclonal antibody, designed to enhance LDL receptor availability, which leads to a notable and sustained reduction in LDL-C. The therapy provides high effectiveness, a favorable safety record, and less frequent dosing in comparison to many conventional lipid-lowering alternatives. By broadening access to children affected by genetic high cholesterol, the product assists in tackling early-onset cardiovascular risk and supports the management of long-term heart health.

Praluent Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

View The Full Praluent Market Report:

https://thebusinessresearchcompany.com/report/praluent-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Praluent Market Regional Breakdown: Where Is Demand Concentrated?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Praluent Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %

Expansion in the historical timeframe can be explained by factors such as the increasing occurrence of high cholesterol, the shortcomings of treatments relying exclusively on statins, broader screening programs for cardiovascular risk, development of biologic therapies for heart conditions, and a rise in specialized cardiology services.

The expansion projected for the forecast period stems from a heightened emphasis on aggressive lipid-lowering approaches, broader use in secondary prevention, the growth of value-based cardiovascular care, stronger payer endorsement for PCSK9 inhibitors, and greater public awareness around reducing cardiovascular risk. Key developments shaping this period involve the growing incorporation of PCSK9 inhibitors into lipid management, their increasing application among high-risk cardiovascular patients, more frequent integration with statin combination therapy, the extension of preventive cardiology initiatives, and a reinforced commitment to achieving long-term LDL control.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Praluent Market Demand Drivers Creating New Revenue Opportunities

The anticipated growth of the praluent market will likely be driven by the rising prevalence of obesity. This condition involves the excessive accumulation of body fat that endangers health, generally identified when an individual has a Body Mass Index (BMI) of 30 or more. Its increasing frequency stems largely from changes in global dietary patterns and food systems, marked by a higher intake of ultra-processed foods, inactive ways of living, and economic conditions that make unhealthy food options more accessible. As a PCSK9 inhibitor, praluent addresses obesity by boosting the liver’s capacity to clear LDL cholesterol from circulation, lowering LDL cholesterol levels in individuals with obesity-related dyslipidemia, and consequently enhancing heart health while mitigating complications linked to obesity. To illustrate, a May 2024 report from the Office for Health Improvement and Disparities—a UK government body overseeing public health strategies—indicated that during 2022–2023, 64.0% of adults aged 18 and over in England were overweight or had obesity, with 26.2% specifically living with obesity (BMI = 30 kg/m²). As a result, the upward trend in obesity will propel the expansion of the praluent market.

The escalating use of personalized medicine is set to fuel growth in the Praluent market moving ahead. In this approach, clinicians customize treatments based on an individual’s distinct biological traits to achieve better health outcomes. Its growing application is fueled by a preference among healthcare providers for therapies that correspond with genetic and biomarker signatures, enabling greater treatment accuracy. Since its targeted action as a PCSK9 inhibitor enables clinicians to customize LDL-cholesterol reduction according to each patient’s cardiovascular risk profile, Praluent is well-suited to support the rise of personalized medicine. Evidence for this comes from BioSpace, Inc., a U.S. life science news platform, which reported in February 2025 that the FDA authorized 16 new personalized therapies for rare disease patients in 2023, a jump from six the prior year. Consequently, the expanding uptake of personalized medicine is anticipated to accelerate the Praluent market’s growth.

Praluent Market Segment Analysis And Revenue Opportunities

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Praluent Market Trends Driving Strategic Industry Expansion

Major players within the praluent market are prioritizing the creation of cutting-edge solutions, including low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the growing need for advanced treatments for cardiovascular risk reduction. These LDL-C–lowering therapies represent specialized medical approaches precisely engineered to drastically decrease levels of “bad cholesterol,” delivering more accurate, targeted, and sustained control over lipids than what is achievable through standard statins or lifestyle adjustments alone. A notable example occurred in March 2024, when Regeneron Pharmaceuticals Inc., a biotechnology firm headquartered in the United States, secured an extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, an advanced biologic therapy designed for LDL-C reduction. This renewed clearance permits its application as a supplementary treatment alongside dietary measures and existing lipid-lowering regimens for pediatric individuals aged 8 and older who are affected by heterozygous familial hypercholesterolemia (HeFH). Praluent acts as a PCSK9 inhibitor monoclonal antibody that enhances LDL receptor accessibility, leading to pronounced and prolonged decreases in LDL-C levels. The therapy is characterized by its strong effectiveness, a reassuring safety profile, and a reduced dosing frequency when compared with numerous conventional lipid-lowering alternatives. By broadening access to children with genetic forms of high cholesterol, this product aids in managing early-emerging cardiovascular hazards and promotes sustained heart health management over the long term.

Praluent Market Leading Players Shaping Industry Direction

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Access The Complete Praluent Market Report:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Praluent Market Regional Analysis: Which Region Leads By Revenue?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Praluent Market?

Historical growth was driven by the increasing incidence of hypercholesterolemia, the inherent limitations of statin-only treatments, and a rise in cardiovascular risk screening. Additionally, the expansion of biologic cardiovascular drugs and the growing availability of specialist cardiology care also contributed significantly.

Projected expansion during the forecast period is driven by an increased emphasis on aggressive strategies for lowering lipids, broader adoption in secondary prevention efforts, the growth of value-based cardiovascular care models, rising support from payers for pcsk9 inhibitors, and a heightened awareness regarding cardiovascular risk reduction.

Major developments expected in the forecast period include the expanding application of pcsk9 inhibitors in lipid management, increasing uptake among high-risk cardiovascular patients, greater integration with statin combination therapies, the enlargement of preventive cardiology programs, and an intensified focus on long-term control of LDL levels.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Which Core Factors Are Supporting The Expansion Of The Praluent Market?

An anticipated increase in obesity is set to stimulate the expansion of the Praluent market. This condition is medically defined by an unhealthy accumulation of body fat that poses health risks, typically indicated by a Body Mass Index (BMI) of 30 or greater. The growing prevalence of obesity is attributed to shifts in global food systems and dietary habits, marked by increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make less healthy food options more accessible. Praluent addresses obesity by functioning as a PCSK9 inhibitor, which enhances the liver’s capacity to remove LDL cholesterol from the bloodstream. This action lowers LDL cholesterol levels in individuals with obesity-related dyslipidemia, thereby improving cardiovascular health and reducing complications associated with obesity. For example, data from May 2024, released by the Office for Health Improvement and Disparities, a UK government department, indicated that an estimated 64.0% of adults (18+) in England were overweight or living with obesity during the 2022–2023 period, with 26.2% specifically living with obesity (BMI ≥ 30 kg/m²). Consequently, the increasing rates of obesity are poised to advance the Praluent market’s expansion.

What Segment Types Are Included In The Praluent Market Analysis?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Trends Are Influencing The Direction Of The Praluent Market?

Major companies within the praluent market are directing their efforts towards creating innovative solutions, including low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the growing demand for advanced treatments that reduce cardiovascular risk. LDL-C–lowering therapies are specialized medical interventions designed to significantly decrease levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained extended U.S. Food and Drug Administration (FDA) approval for Praluent (alirocumab) injection, an advanced LDL-C–lowering biologic therapy. This updated authorization permits its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older who have heterozygous familial hypercholesterolemia (HeFH). Praluent operates as a PCSK9 inhibitor monoclonal antibody, formulated to enhance LDL receptor availability, resulting in a marked and sustained reduction in LDL-C. The therapy offers strong efficacy, a favorable safety profile, and less frequent dosing when compared to many traditional lipid-lowering options. By broadening access to children with genetic high cholesterol, the product contributes to managing early-onset cardiovascular risk and supports long-term heart health management.

Who Are The Companies Shaping The Praluent Market Landscape?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Access The Complete Praluent Market Report:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Stands As The Largest Contributor To The Praluent Market?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Praluent Market Progress Between 2026 And 2030?

The growth observed during the historic period was largely a result of the increasing prevalence of hypercholesterolemia, the identified limitations of therapies that only use statins, an expansion in cardiovascular risk screening initiatives, the wider availability of biologic cardiovascular drugs, and the growing provision of specialist cardiology care.

The anticipated growth during the forecast period is attributed to an intensifying emphasis on robust lipid-lowering strategies, greater adoption in secondary prevention, the expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, and heightened awareness of cardiovascular risk reduction. Major trends projected for this period include the increasing use of pcsk9 inhibitors in lipid management, rising adoption among high-risk cardiovascular patients, growing integration with statin combination therapy, the expansion of preventive cardiology programs, and an enhanced focus on long-term ldl control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

What Key Factors Are Shaping The Praluent Market Landscape?

An anticipated increase in obesity is set to stimulate the expansion of the Praluent market. This condition is medically defined by an unhealthy accumulation of body fat that poses health risks, typically indicated by a Body Mass Index (BMI) of 30 or greater. The growing prevalence of obesity is attributed to shifts in global food systems and dietary habits, marked by increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make less healthy food options more accessible. Praluent addresses obesity by functioning as a PCSK9 inhibitor, which enhances the liver’s capacity to remove LDL cholesterol from the bloodstream. This action lowers LDL cholesterol levels in individuals with obesity-related dyslipidemia, thereby improving cardiovascular health and reducing complications associated with obesity. For example, data from May 2024, released by the Office for Health Improvement and Disparities, a UK government department, indicated that an estimated 64.0% of adults (18+) in England were overweight or living with obesity during the 2022–2023 period, with 26.2% specifically living with obesity (BMI = 30 kg/m²). Consequently, the increasing rates of obesity are poised to advance the Praluent market’s expansion.

How Is The Praluent Market Segmented Across Different Segment Categories?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Trends Are Impacting The Progress Of The Praluent Market?

Major companies in the praluent market are concentrating on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to satisfy the increasing demand for advanced cardiovascular risk-reduction treatments. These LDL-C–lowering therapies are specialized medical interventions created to significantly decrease levels of “bad cholesterol,” offering more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) extended approval for Praluent (alirocumab) injection, which is an advanced LDL-C–lowering biologic therapy. This updated approval allows its application as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Praluent operates as a PCSK9 inhibitor monoclonal antibody designed to enhance LDL receptor availability, leading to a marked and sustained LDL-C reduction. The therapy offers high efficacy, a favorable safety profile, and less frequent dosing compared to many traditional lipid-lowering options. By expanding access to children with genetic high cholesterol, the product helps address early-onset cardiovascular risk and supports long-term heart health management.

Which Organizations Play A Role In The Praluent Market Landscape?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Get The Full Praluent Market Report:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Where Is The Praluent Market Primarily Concentrated By Region?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Praluent Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Praluent Market Expected To Change Between 2026 And 2030?

The expansion observed during the historical timeframe can be linked to the rising occurrence of hypercholesterolemia, the inherent inadequacies of treatments relying solely on statins, more frequent assessments for cardiovascular danger, the increasing availability of biological medications for heart conditions, and the growth in specialized heart care services.

The projected growth during the forecast period stems from an increased emphasis on aggressive lipid reduction strategies, a rising adoption in secondary prevention efforts, the expansion of value-based cardiovascular care services, growing financial support from payers for PCSK9 inhibitors, and heightened awareness regarding cardiovascular risk mitigation.

Major anticipated trends throughout the forecast period include the increasing utilization of PCSK9 inhibitors in lipid management, a growing prevalence of their adoption among high-risk cardiovascular patients, greater integration with statin combination therapies, the expansion of preventive cardiology initiatives, and an enhanced dedication to long-term LDL control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

What Drivers Are Expected To Influence The Praluent Market During The Forecast Period?

The future expansion of the **Praluent market** is anticipated to be fueled by the growing incidence of obesity. This medical condition involves an unhealthy accumulation of body fat, generally identified by a Body Mass Index (BMI) of 30 or greater, which poses health risks. The increasing occurrence of obesity stems primarily from changes in global dietary patterns and food systems, including higher intake of ultra-processed items, less physical activity, and economic factors that favor less healthy food options. **Praluent** aids in managing obesity by lowering LDL cholesterol in individuals with dyslipidemia linked to obesity. As a PCSK9 inhibitor, it boosts the liver’s efficiency in clearing LDL cholesterol from the bloodstream, thereby enhancing cardiovascular well-being and mitigating obesity-related health issues. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK-based government body overseeing public health, indicated that an estimated 64.0% of adults (18+) in England were overweight or obese between 2022 and 2023, with 26.2% specifically living with obesity (BMI ≥ 30 kg/m²). Consequently, the upward trend in obesity is set to propel the growth of the **Praluent market**. The growing embrace of personalized medicine is set to stimulate the expansion of the **Praluent market** in the future. Personalized medicine involves customizing treatments based on an individual’s unique biological traits to achieve superior patient outcomes. The increased acceptance of this approach is due to a growing inclination among medical professionals for treatments that precisely match genetic and biomarker profiles, leading to more accurate care. **Praluent** contributes to the rise of personalized medicine by offering a targeted PCSK9-inhibiting mechanism, which enables clinicians to adjust LDL-cholesterol reduction specifically to a patient’s cardiovascular risk profile. As an illustration, in February 2025, BioSpace, Inc., a U.S.-based life science news site, reported that the FDA cleared 16 new personalized treatments for patients with rare diseases in 2023, an increase from six approvals in 2022. Consequently, the rising adoption of personalized medicine is projected to propel the growth of the **Praluent market**.

How Is The Praluent Market Structured Across Different Segments?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Trends Are Shaping The Future Of The Praluent Market?

Key companies within the praluent market are prioritizing the development of innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to fulfill the growing demand for advanced treatments that reduce cardiovascular risk. LDL-C–lowering therapies are specialized medical interventions designed to significantly decrease levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to using traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained U.S. Food and Drug Administration (FDA) extended approval for Praluent (alirocumab) injection, an advanced LDL-C–lowering biologic therapy. This updated approval permits its use as an adjunct to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). Praluent is a PCSK9 inhibitor monoclonal antibody engineered to boost LDL receptor availability, leading to a notable and lasting reduction in LDL-C. The therapy offers high efficacy, a favorable safety profile, and less frequent dosing compared to many conventional lipid-lowering options. By broadening access to children with genetic high cholesterol, the product assists in addressing early-onset cardiovascular risk and supports long-term heart health management.

Which Major Players Dominate The Praluent Market?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Read the full praluent market report here:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Is Forecast To Lead The Praluent Market In Terms Of Market Size?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Praluent Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the praluent market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Praluent Market size between 2026 and 2035?

Historically, the observed growth was due to an escalating prevalence of hypercholesterolemia, the inherent limitations of therapies relying solely on statins, enhanced cardiovascular risk screening efforts, the broadening availability of biologic cardiovascular drugs, and an increase in specialized cardiology care.

The projected growth during the forecast period can be attributed to an increased focus on aggressive lipid-lowering strategies, rising adoption in secondary prevention, the expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, and a heightened awareness of cardiovascular risk reduction.

Major trends anticipated in the forecast period include the increasing use of pcsk9 inhibitors in lipid management, rising adoption among high-risk cardiovascular patients, growing integration with statin combination therapy, the expansion of preventive cardiology programs, and an enhanced focus on long-term ldl control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Which Drivers Are Impacting Market Performance In The Praluent Market?

The Praluent market is anticipated to grow due to the increasing prevalence of obesity. Obesity is defined as a medical state where excessive body fat accumulates, posing health risks, typically identified by a Body Mass Index (BMI) of 30 or greater. The increasing incidence of obesity stems primarily from changes in global dietary patterns and eating behaviors, marked by greater intake of ultra-processed foods, inactive lifestyles, and economic factors that make less healthy food options more accessible. Praluent aids in managing obesity by lowering LDL cholesterol levels in individuals suffering from obesity-related dyslipidemia; as a PCSK9 inhibitor, it boosts the liver’s capacity to clear LDL cholesterol from the bloodstream, thereby enhancing cardiovascular wellness and mitigating complications linked to obesity. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK government body focused on public health, indicated that an estimated 64.0% of adults (18+) in England were either overweight or living with obesity between 2022 and 2023, with 26.2% specifically estimated to be living with obesity (BMI = 30 kg/m²). Consequently, the upward trend in obesity will propel the Praluent market’s expansion. The Praluent market is set for expansion driven by the growing integration of personalized medicine. Personalized medicine is an approach to treatment where medical professionals customize therapies based on a patient’s unique biological traits to enhance treatment efficacy. The increasing uptake of personalized medicine is due to a rising preference among clinicians for treatments that precisely match genetic and biomarker profiles, leading to more accurate therapeutic outcomes. Praluent facilitates the expanded use of personalized medicine as its specific PCSK9-inhibiting action enables clinicians to customize reductions in LDL-cholesterol according to each patient’s cardiovascular risk profile. As an illustration, in February 2025, BioSpace, Inc., a U.S. life science news platform, reported that in 2023, the FDA had approved 16 novel personalized treatments for patients with rare diseases, an increase from six approvals in 2022. Consequently, the rising adoption of personalized medicine is projected to propel the Praluent market forward.

Which Segments Are Contributing To The Growth Of The Praluent Market?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Competitive Trends Are Impacting The Structure Of The Praluent Market?

Leading companies in the praluent market are concentrating on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the increasing demand for advanced cardiovascular risk-reduction treatments. These LDL-C–lowering therapies are specialized medical interventions designed to significantly reduce levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, which is an advanced LDL-C–lowering biologic therapy. This updated approval permits its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older who have heterozygous familial hypercholesterolemia (HeFH). Praluent functions as a PCSK9 inhibitor monoclonal antibody, designed to enhance LDL receptor availability, leading to a marked and sustained reduction in LDL-C. The therapy offers strong efficacy, a favorable safety profile, and less frequent dosing when compared to many conventional lipid-lowering options. By expanding access to children with genetic high cholesterol, the product helps in addressing early-onset cardiovascular risk and supports long-term heart health management.

Who Are The Top-Performing Companies In The Praluent Market In Recent Years?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Currently Holds The Largest Share Of The Praluent Market?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Praluent Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the praluent market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Praluent Market size between 2026 and 2035?

Historically, the observed growth was due to an escalating prevalence of hypercholesterolemia, the inherent limitations of therapies relying solely on statins, enhanced cardiovascular risk screening efforts, the broadening availability of biologic cardiovascular drugs, and an increase in specialized cardiology care.

The projected growth during the forecast period can be attributed to an increased focus on aggressive lipid-lowering strategies, rising adoption in secondary prevention, the expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, and a heightened awareness of cardiovascular risk reduction.

Major trends anticipated in the forecast period include the increasing use of pcsk9 inhibitors in lipid management, rising adoption among high-risk cardiovascular patients, growing integration with statin combination therapy, the expansion of preventive cardiology programs, and an enhanced focus on long-term ldl control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Which Drivers Are Impacting Market Performance In The Praluent Market?

The Praluent market is anticipated to grow due to the increasing prevalence of obesity. Obesity is defined as a medical state where excessive body fat accumulates, posing health risks, typically identified by a Body Mass Index (BMI) of 30 or greater. The increasing incidence of obesity stems primarily from changes in global dietary patterns and eating behaviors, marked by greater intake of ultra-processed foods, inactive lifestyles, and economic factors that make less healthy food options more accessible. Praluent aids in managing obesity by lowering LDL cholesterol levels in individuals suffering from obesity-related dyslipidemia; as a PCSK9 inhibitor, it boosts the liver’s capacity to clear LDL cholesterol from the bloodstream, thereby enhancing cardiovascular wellness and mitigating complications linked to obesity. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK government body focused on public health, indicated that an estimated 64.0% of adults (18+) in England were either overweight or living with obesity between 2022 and 2023, with 26.2% specifically estimated to be living with obesity (BMI = 30 kg/m²). Consequently, the upward trend in obesity will propel the Praluent market’s expansion. The Praluent market is set for expansion driven by the growing integration of personalized medicine. Personalized medicine is an approach to treatment where medical professionals customize therapies based on a patient’s unique biological traits to enhance treatment efficacy. The increasing uptake of personalized medicine is due to a rising preference among clinicians for treatments that precisely match genetic and biomarker profiles, leading to more accurate therapeutic outcomes. Praluent facilitates the expanded use of personalized medicine as its specific PCSK9-inhibiting action enables clinicians to customize reductions in LDL-cholesterol according to each patient’s cardiovascular risk profile. As an illustration, in February 2025, BioSpace, Inc., a U.S. life science news platform, reported that in 2023, the FDA had approved 16 novel personalized treatments for patients with rare diseases, an increase from six approvals in 2022. Consequently, the rising adoption of personalized medicine is projected to propel the Praluent market forward.

Which Segments Are Contributing To The Growth Of The Praluent Market?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Competitive Trends Are Impacting The Structure Of The Praluent Market?

Leading companies in the praluent market are concentrating on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the increasing demand for advanced cardiovascular risk-reduction treatments. These LDL-C–lowering therapies are specialized medical interventions designed to significantly reduce levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, which is an advanced LDL-C–lowering biologic therapy. This updated approval permits its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older who have heterozygous familial hypercholesterolemia (HeFH). Praluent functions as a PCSK9 inhibitor monoclonal antibody, designed to enhance LDL receptor availability, leading to a marked and sustained reduction in LDL-C. The therapy offers strong efficacy, a favorable safety profile, and less frequent dosing when compared to many conventional lipid-lowering options. By expanding access to children with genetic high cholesterol, the product helps in addressing early-onset cardiovascular risk and supports long-term heart health management.

Who Are The Top-Performing Companies In The Praluent Market In Recent Years?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Currently Holds The Largest Share Of The Praluent Market?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Praluent Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Praluent Market from 2024 to 2025?

In recent years, the Praluent market has expanded by XX (HCAGR). It is projected to rise from $XX million in 2024 to $XX million in 2025, demonstrating a compound annual growth rate (CAGR) of XX%. This growth during the historical period is owed to factors such as escalation in older populations, increased expenditure on cholesterol management drugs, heightened awareness of healthcare, the growing requirement for advanced treatments for hypercholesterolemia, and the worldwide rise in heart disease and hypercholesterolemia.

What Is the Projected Market Size of the Praluent Market?

Expectations are set for the Praluent market size to experience an XX% compound annual growth rate (FCAGR) in the coming years, eventually reaching a value of $XX million in 2029. There are several factors contributing to this forecasted growth period. These include heightening incidences of cardiovascular diseases, improved awareness around managing hyperlipidemia, increasing demand for successful treatments in lowering cholesterol, wider use of PCSK9 inhibitors, increased use of personalized medicine, and a rise in healthcare investments. Anticipated trends throughout this growth period include the creation of higher-dose formulations, progress in drug delivery devices, the incorporation of digital health technologies for remote monitoring, breakthroughs in biotechnology, and growing usage of personalized medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Who are the Major Competitors in the Praluent Market Outlook?

Major companies operating in the praluent market are Sanofi S.A.; Regeneron Pharmaceuticals Inc.

What Is Fueling Growth in the Praluent Market?

The growth of the praluent market is anticipated to be fueled by the increasing occurrence of cardiovascular diseases. Such diseases pertain to a collection of disorders that affect the heart and blood vessels, including ailments like coronary artery disease, heart attacks, and strokes. The escalating occurrence of these diseases is primarily attributable to the rising rates of unhealthy lifestyles, such as poor eating habits, physical inactivity, and increased consumption of tobacco and alcohol. Praluent is specifically designed to manage cardiovascular diseases by reducing LDL cholesterol via PCSK9 inhibition, which consequentially minimizes the risk associated with heart attacks and strokes. For instance, data from the Office for National Statistics, a UK-based official department, revealed that 3.6 million individuals had a cardiovascular condition (6.4%), 3.7 million had a respiratory disease (6.8%), and 6.6 million people (12.1%) had either of these conditions as of March 2021. Hence, the escalation in the incidence of cardiovascular diseases is propelling the expansion of the praluent market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Which Praluent Market Segments Are Growing the Fastest?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies

3) By End-User: Ambulatory Care; Home Care

Which Industry Trends Are Shaping the Future of the Praluent Market?

The praluent market’s primary trend is centred on the advancement of pioneering solutions like low-density lipoprotein cholesterol (LDL-C) reduction therapies in order to improve and maximize patient care precision and efficacy. LDL-C lowering therapies are essentially medical procedures designed to minimize bad cholesterol levels in the bloodstream and thus reduce the potential for cardiovascular conditions such as heart attacks and strokes. In March 2024, for example, Regeneron Pharmaceuticals Inc., an American biotechnology firm, gained expanded approval from the U.S. Food and Drug Administration (FDA) for its praluent (alirocumab) injection to treat children suffering from a genetic high cholesterol condition. This approval has now been widened to include its application as an addition to diet and other LDL-C reduction therapies for children aged 8 and above with heterozygous familial hypercholesterolemia (HeFH). This strategy specifically caters to the needs of children and mitigates the cardiovascular risks in young patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Countries Are Leading the Praluent Market?

North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20261

This Report Delivers Insight On:

1. How big is the praluent market, and how is it changing globally?

2. Who are the major companies in the praluent market, and how are they performing?

3. What are the key opportunities and risks in the praluent market right now?

4. Which products or customer segments are growing the most in the praluent market?

5. What factors are helping or slowing down the growth of the praluent market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Are the Projected Market Size and Growth Rates for the Praluent Market From 2025 To 2029?

The market size of praluent has witnessed a XX (HCAGR) enhancement lately. It is projected to prosper from $XX million in 2024 to $XX million in 2025, rising at a compound annual growth rate (CAGR) of XX%. Various factors such as the rise in the elderly population, enhanced expenditure on cholesterol management drugs, increased cognizance about health care, the growing requirement for refined treatments for hypercholesterolemia, and a global upsurge in hypercholesterolemia and cardiovascular ailments have been crucial contributors to the growth in this historical period.

In the coming years, the market size of Praluent is projected to experience an XX (FCAGR). By 2029, it is expected to expand to $XX million at a compound annual growth rate (CAGR) of XX%. The growth during the predicted period can be credited to an uptick in cardiovascular diseases, heightened awareness about the management of hyperlipidemia, an increased demand for effective treatments for reducing cholesterol, the growing application of PCSK9 inhibitors, a rise in the adoption of personalized medicine, and escalating investments in healthcare. The major trends observed during the forecast period incorporate the creation of higher-dose formulas, progress in drug delivery devices, combination with digital health technologies for remote monitoring, advancements in biotechnology, and increased uptake of personalized medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Praluent Market?

An increase in the occurrence of cardiovascular diseases is predicted to fuel the expansion of the praluent market. Cardiovascular diseases encompass a range of afflictions impacting the heart and blood vessels such as coronary artery disease, heart attacks, and strokes. The surge in cardiovascular diseases is largely due to the escalating unhealthy lifestyle patterns, including inadequate diet, lack of physical activity, and intensified tobacco and alcohol consumption. Praluent aids in the control of cardiovascular diseases by reducing LDL cholesterol levels through PCSK9 inhibition, thus decreasing the likelihood of heart attacks and strokes. For example, records from the Office for National Statistics, a governmental department in the UK, indicated that in December 2022, 3.6 million individuals were experiencing cardiovascular ailment (6.4%), 3.7 million were living with a respiratory disease (6.8%), and 6.6 million people (12.1%) had one of these illnesses in March 2021. Consequently, the escalation in the incidence of cardiovascular diseases accelerates the praluent market’s growth.

Which Key Market Segments Comprise the Praluent Market and Drive Its Revenue Growth?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies

3) By End-User: Ambulatory Care; Home Care

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Which Areas Are Leading Regions in the Praluent Market Expansion Across the Globe?

North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Praluent Market Over the Coming Years?

A primary trend observable in the praluent market is the emphasis on developing progressive solutions, like therapies reducing low-density lipoprotein cholesterol (LDL-C), in a bid to augment and streamline patient care’s exactness and efficiency. LDL-C lowering therapies are medical interventions that aim to lower the levels of LDL cholesterol, often referred to as ‘bad cholesterol’, in the blood, reducing the likelihood of cardiovascular conditions such as strokes and heart attacks. For instance, Regeneron Pharmaceuticals Inc., a biotechnology company based in the US, gained an extension for praluent (alirocumab) use from the U.S. Food and Drug Administration (FDA) in March 2024, allowing it to treat children suffering from a genetic variant of high cholesterol. The permission now includes its use as an add-on to diet and additional LDL- C lowering treatments for pediatric patients as young as 8 with heterozygous familial hypercholesterolemia (HeFH). This particular strategy caters to the needs of children and decreases cardiovascular threats in younger patients.

View the full report here:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

How Is the Praluent Market Conceptually Defined?

Praluent is a monoclonal antibody used to treat high cholesterol levels, specifically low-density lipoprotein (LDL) cholesterol, known as bad cholesterol. It is used for treating adults with primary hypercholesterolemia or mixed dyslipidemia and reducing cardiovascular risk in patients with established heart disease.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20261

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Praluent Market?

The rise in prevalence of cardiovascular diseases is expected to propel the growth of the praluent market going forward. Cardiovascular diseases refer to a group of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart attacks, and strokes. The rising prevalence of cardiovascular diseases is primarily due to growing rates of unhealthy lifestyles, including poor diet, physical inactivity, and increased tobacco and alcohol use. Praluent helps manage cardiovascular diseases by lowering LDL cholesterol through PCSK9 inhibition, reducing the risk of heart attacks and strokes. For instance, in December 2022, according to the Office for National Statistics, a UK-based government department, 3.6 million people had a cardiovascular condition (6.4%), 3.7 million had a respiratory disease (6.8%), and 6.6 million people (12.1%) had one of these conditions in March 2021. Therefore, the rise in the prevalence of cardiovascular diseases drives the growth of the praluent market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

What is the Predicted Annual Growth Rate of thePraluent Market Impact Industry Trends by 2034?

The praluent market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to growing aging population, increasing spending on cholesterol management medications, increasing healthcare awareness, growing need for advanced hypercholesterolemia treatments, escalating prevalence of hypercholesterolemia and cardiovascular diseases worldwide.

The praluent market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, growing awareness of hyperlipidemia management, rising demand for effective cholesterol-lowering treatments, expanding use of PCSK9 inhibitors, increasing adoption of personalized medicine, and rising healthcare investments. Major trends in the forecast period include the development of higher-dose formulations, advancements in drug delivery devices, integration with digital health technologies for remote monitoring, advancements in biotechnology, and the adoption of personalized medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20261

What Are the Key Market Innovations in thePraluent Market Over the Coming Years?

The key trend in the praluent market is focusing on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to streamline and enhance the effectiveness and precision of patient care. Low-density lipoprotein cholesterol (LDL-C) lowering therapies refer to medical treatments designed to reduce levels of LDL cholesterol, commonly known as ‘bad cholesterol,’ in the blood to decrease the risk of cardiovascular diseases, such as heart attacks and strokes. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received the U.S. Food and Drug Administration (FDA) extended approval of praluent (alirocumab) injection to treat children with a genetic form of high cholesterol. This approval has been extended to include its use as an add-on to diet and other LDL-C-lowering therapies for pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). This approach specifically addresses the needs of children and reduces cardiovascular risks in young patients.

Who Are the Top Companies Driving Innovation and Growth in thePraluent Market?

Major companies operating in the praluent market are Sanofi S.A.; Regeneron Pharmaceuticals Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Key Market Segments Comprise the Praluent Market and Drive Its Revenue Growth?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies

3) By End-User: Ambulatory Care; Home Care

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Which Regions Are Emerging as Leaders in the Praluent Market?

North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Praluent Market 2025, By The Business Research Company:

Cardiovascular Ultrasound Global Market Report 2025

https://thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

Angina Pectoris Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Global Cardiometabolic Diseases Global Market Report 2025

https://thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: